Intrahepatic Cholangiocarcinoma — Trials

Intrahepatic Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 88
Recruiting: 53
Ph III recruiting: 2
Growth YoY: +23.8%
Industry share: 9%
Top sponsor: Fudan University
Termination share: 47.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04669496	Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors	active not recruiting	Phase 2 / Phase 3	178	Shanghai Zhongshan HospitalOTHER	1	Sep 4, 2025	clinicaltrials

Data updated 22 days agoSource updated Sep 4, 2025source: clinicaltrials